Underscoring the potency of SPPL3 as a regulator of cellular glycosylation, numerous unbiased cell-based genetic screens have since linked loss of SPPL3 to overt phenotypes such as glycosylation-dependent tumor immune evasion (Dufva et al, 2020; Jongsma et al, 2021; Heard et al, 2022; Dufva et al, 2023; Zhuang et al, 2024). Here, SPPL3 is linked to neoplasm.